Immatics (IMTX) Competitors $6.56 +0.11 (+1.71%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$6.56 0.00 (0.00%) As of 07/25/2025 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMTX vs. CRNX, MOR, ALVO, MIRM, CPRX, GMTX, AMRX, NAMS, RARE, and OGNShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Ultragenyx Pharmaceutical (RARE), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. Immatics vs. Its Competitors Crinetics Pharmaceuticals MorphoSys Alvotech Mirum Pharmaceuticals Catalyst Pharmaceuticals Gemini Therapeutics Amneal Pharmaceuticals NewAmsterdam Pharma Ultragenyx Pharmaceutical Organon & Co. Crinetics Pharmaceuticals (NASDAQ:CRNX) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Is CRNX or IMTX more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Immatics' net margin of -14.73%. Immatics' return on equity of -4.52% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -30.95% -28.12% Immatics -14.73%-4.52%-3.34% Which has better valuation and earnings, CRNX or IMTX? Immatics has higher revenue and earnings than Crinetics Pharmaceuticals. Immatics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$760K3,817.85-$298.41M-$3.82-8.11Immatics$144.15M5.53$16.47M-$0.17-38.59 Do analysts prefer CRNX or IMTX? Crinetics Pharmaceuticals currently has a consensus price target of $69.50, indicating a potential upside of 124.27%. Immatics has a consensus price target of $14.67, indicating a potential upside of 123.58%. Given Crinetics Pharmaceuticals' higher probable upside, equities analysts plainly believe Crinetics Pharmaceuticals is more favorable than Immatics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80Immatics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media favor CRNX or IMTX? In the previous week, Crinetics Pharmaceuticals had 5 more articles in the media than Immatics. MarketBeat recorded 7 mentions for Crinetics Pharmaceuticals and 2 mentions for Immatics. Crinetics Pharmaceuticals' average media sentiment score of 1.48 beat Immatics' score of 0.93 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, CRNX or IMTX? Crinetics Pharmaceuticals has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Do institutionals & insiders have more ownership in CRNX or IMTX? 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 3.3% of Immatics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryCrinetics Pharmaceuticals beats Immatics on 9 of the 17 factors compared between the two stocks. Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$784.00M$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-38.5921.1828.1020.05Price / Sales5.53288.50432.4490.07Price / Cash26.4042.7636.2258.56Price / Book1.288.378.665.87Net Income$16.47M-$55.19M$3.25B$258.55M7 Day Performance9.33%5.88%4.23%3.74%1 Month Performance17.35%17.33%10.52%11.75%1 Year Performance-46.67%4.42%34.41%18.03% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics2.805 of 5 stars$6.56+1.7%$14.67+123.6%-47.1%$784.00M$144.15M-38.59260News CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.685 of 5 stars$30.95-0.5%$69.50+124.6%-41.9%$2.91B$1.04M-8.10210Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ALVOAlvotech2.7142 of 5 stars$8.64+0.1%$16.00+85.2%-14.9%$2.60B$491.98M23.351,032MIRMMirum Pharmaceuticals3.8631 of 5 stars$51.95+0.0%$65.50+26.1%+28.4%$2.57B$336.89M-32.27140Positive NewsCPRXCatalyst Pharmaceuticals4.9239 of 5 stars$21.01-0.1%$32.83+56.3%+20.7%$2.57B$491.73M13.3880News CoveragePositive NewsAnalyst RevisionGMTXGemini TherapeuticsN/A$57.770.0%N/A+36.0%$2.50BN/A-57.7730High Trading VolumeAMRXAmneal Pharmaceuticals3.1469 of 5 stars$7.91-0.8%$11.60+46.6%+9.2%$2.50B$2.83B-197.708,100NAMSNewAmsterdam Pharma3.5369 of 5 stars$22.56+1.6%$41.30+83.1%+26.1%$2.49B$45.56M-12.004RAREUltragenyx Pharmaceutical4.373 of 5 stars$26.39+0.3%$83.64+216.9%-39.3%$2.49B$560.23M-4.491,294Upcoming EarningsGap DownHigh Trading VolumeOGNOrganon & Co.4.7712 of 5 stars$9.43-0.4%$18.00+91.0%-53.9%$2.46B$6.40B3.274,000 Related Companies and Tools Related Companies Crinetics Pharmaceuticals Competitors MorphoSys Competitors Alvotech Competitors Mirum Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors Gemini Therapeutics Competitors Amneal Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Ultragenyx Pharmaceutical Competitors Organon & Co. Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMTX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMTX Stock Alerts